Research explores insulin dysfunction as a potential factor in Alzheimer’s disease

Scientists investigate the ‘type 3 diabetes’ concept, highlighting insulin’s role in brain health and cognitive decline, yet caution that the theory remains unproven as a clinical diagnosis.

For more than two decades, some researchers have used the term “type 3 diabetes” to describe a possible biological link between impaired insulin signalling in the brain and Alzheimer’s disease. The idea has attracted attention because it offers one way to explain why some people with dementia show problems with glucose metabolism, inflammation and energy use in brain cells, but it remains a theory rather than an accepted medical diagnosis.

According to reporting by Science Alert, the concept has been discussed as a way of describing how insulin dysfunction in the brain might contribute to memory loss and cognitive decline. Research summaries from Healthline, Medical News Today and WebMD all note that the label is not officially recognised by health authorities and is not used by most doctors for diagnosis. Instead, it is best understood as a shorthand for an area of research, not as a separate disease.

The scientific interest comes from the role insulin may play beyond the pancreas. Scientists have identified insulin activity in the brain, including in regions involved in learning, memory and broader metabolic regulation. Studies indexed on PubMed, including work published in 2005 and 2019, have explored whether insulin resistance, impaired insulin-like growth factor signalling, and reduced glucose use in the brain could help drive the processes that damage neurons in Alzheimer’s disease.

That evidence has encouraged some researchers to argue that Alzheimer’s may have a metabolic component, especially in cases where brain cells cannot properly take up and use glucose. But the same literature also stresses caution. Alzheimer’s is a complex condition with multiple possible causes, and several scientists warn that calling it type 3 diabetes may oversimplify a disease that likely develops through more than one pathway. For now, the phrase remains a research framework, not a clinical label, even as the relationship between metabolic health, insulin function and brain disease continues to draw attention.